Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.35 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13724845 | 0.89 | PTH1R (0.38) | PTH1ROPRL1 | |
| SCHEMBL14404788 | 0.85 | PRMT1 (0.40) | RXFP1PTH1ROPRL1 | |
| SCHEMBL13723956 | 0.85 | PRMT1 (0.40) | RXFP1PTH1ROPRL1 | |
| SCHEMBL14404950 | 0.84 | PRMT1 (0.39) | RXFP1PTH1ROPRL1 | |
| SCHEMBL2367841 | 0.84 | PRMT1 (0.39) | RXFP1PTH1ROPRL1 | |
| SCHEMBL2367849 | 0.84 | PRMT1 (0.39) | RXFP1PTH1ROPRL1 | |
| SCHEMBL16318368 | 0.84 | PRMT1 (0.38) | PTH1R | |
| SCHEMBL4094614 | 0.83 | OPRM1 (0.34) | KEAP1OPRL1 | |
| SCHEMBL4092095 | 0.83 | OPRM1 (0.34) | KEAP1OPRL1 | |
| SCHEMBL14404798 | 0.83 | RXFP4 (0.40) | RXFP1PTH1ROPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | RXFP1 355/4885PTH1R 290/4885KEAP1 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.